CN203400400U - Polylactic acid paster used for esophagus cancer operation - Google Patents
Polylactic acid paster used for esophagus cancer operation Download PDFInfo
- Publication number
- CN203400400U CN203400400U CN201320406721.3U CN201320406721U CN203400400U CN 203400400 U CN203400400 U CN 203400400U CN 201320406721 U CN201320406721 U CN 201320406721U CN 203400400 U CN203400400 U CN 203400400U
- Authority
- CN
- China
- Prior art keywords
- polylactic acid
- paster
- esophagus cancer
- anastomotic
- fistula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The utility model belongs to the field of medical instruments and discloses a polylactic acid paster used for an esophagus cancer operation. The polylactic acid paster used for the esophagus cancer operation comprises polylactic acid films which are stacked and a polylactic acid frame wrapping the polylactic acid films, wherein epidermal growth factor layers are arranged between every two adjacent polylactic acid films which are stacked. The polylactic acid paster used for the esophagus cancer operation overcomes the defects that during an existing esophagus cancer excision operation or an existing esophagus-stomach anastomosis, anastomotic fistula can occur easily, it is difficult to control the growth of an anastomotic stoma, and the occurrence rate of the anastomotic fistula is high due to the fact that treatment is unavailable before the anastomotic fistula occurs. The polylactic acid paster used for the esophagus cancer operation can promote the growth and union of the anastomotic stoma, and the occurrence rate of the anastomotic fistula can be reduced.
Description
Technical field
This utility model belongs to medical instruments field, is specifically related to a kind of polylactic acid paster that is applied to Operation on Esophageal Cancer.
Background technology
Fistula of operative incision is modal severe complication after Operation on Esophageal Cancer, is also main causes of death.The experience accumulation of processing along with raising and the peri-operation period of surgical operation of esophagus technology in recent years, the particularly clinical practice of coinciding machine, incidence rate and the mortality rate of fistula of operative incision obviously reduce, but its occurrence factor is very complicated, various operation methods all can not guarantee not occur fistula mouth, how reducing fistula of operative incision incidence rate, is that Operation on Esophageal Cancer and peri-operation period are processed the major issue that need to face.
The reason that fistula of operative incision occurs is very complicated, has many-sided factor, most importantly closely related with anastomosis and operation technique, and anastomotic stoma local infection and identical backward pull excessive etc.At present, the Resection Esophagus Carcinoma of improvement, esophageal-gastric anastomosis at home and abroad has and carries out, mainly focus on the protection of strengthening anastomotic stoma, comprise application stomach nethike embrane, Intercostal muscle or pectoralis major band base of a fruit musculo cutaneous flap are strengthened anastomotic stoma, reduce anastomotic stoma tension force, improving blood supplies, to reducing fistula of operative incision, occur, there is certain positive effect, but after having performed the operation, the upgrowth situation of anastomotic stoma is difficult to control, before fistula of operative incision occurs, cannot further process treatment, unlike surface wound or wound surface, can apply a series of measure, promote its healing, thereby cause the incidence rate of fistula of operative incision high.
Utility model content
The technical problems to be solved in the utility model is in the identical operation of existing Resection Esophagus Carcinoma, esophageal-gastric, fistula of operative incision easily occurring, the upgrowth situation of anastomotic stoma is difficult to control, fistula of operative incision cannot be treated the shortcoming that causes fistula of operative incision incidence rate high before occurring, a kind of growth healing that promotes anastomotic stoma is provided, reduces the polylactic acid paster that is applied to Operation on Esophageal Cancer of fistula of operative incision incidence rate.
In order to solve the problems of the technologies described above, this utility model provides following technical scheme: the polylactic acid paster that is applied to Operation on Esophageal Cancer, comprise the polylactic acid membrane stacking and be wrapped in the polylactic acid frame outside polylactic acid membrane, in the polylactic acid membrane stacking, between every layer of polylactic acid membrane, being provided with epidermal growth factor sublayer.
Adopt the polylactic acid paster that is applied to Operation on Esophageal Cancer of technical solutions of the utility model, comprise the polylactic acid membrane stacking and be wrapped in the polylactic acid frame outside polylactic acid membrane, in the polylactic acid membrane stacking, between every layer of polylactic acid membrane, be provided with epidermal growth factor sublayer.Polylactic acid, also referred to as polylactide, belongs to polyester family.Polylactic acid is to take the polymer that lactic acid obtains as primary raw material polymerization, and raw material sources fully and can regenerate; In addition, polylactic acid has tight security can being absorbed by tissue to human body, its good physical and mechanical properties in addition, and the paster framework that is applied to fistula of operative incision is safe and convenient.Epidermal growth factor is abbreviated as EGF, it is the somatomedin of finding the earliest, exchanging ganglion cell's growth, propagation and differentiation plays an important role, by receptor EGF-R ELISA (EGFR) combination with cell surface, work, excite the activity of the tyrosine kinase of receptor inherence, thereby started signal transduction cascade and caused multiple biochemical change, intracellular Ca2+ level rises, increase glycolysis and protein synthesis, increase the expression of (comprising EGF-R ELISA EGFR) of some gene, finally cause DNA to synthesize and cell proliferation.Existing studies confirm that, epidermal growth factor (EGF) all has extremely strong short increment effect to mucous epithelium and myocyte, and can obviously reduce the formation of scar tissue.The framework that polylactic acid is made supports the polylactic acid membrane stacking fixing, in the polylactic acid membrane stacking, between every layer of polylactic acid membrane, be provided with epidermal growth factor sublayer, when performing the operation, esophageal carcinoma is attached to stoma site, epidermal growth factor sublayer is local uninterrupted free list skin growth factor (EGF), maintain 7-10 days deenergized period, promote the growth healing of anastomotic stoma, avoid to a certain extent the generation of fistula of operative incision, thereby reduce the incidence rate of fistula of operative incision.
Further, described polylactic acid membrane width 20-50mm, length 80-100mm; Described polylactic acid frame length, width are 3-8mm, and thickness is 1mm.Applicable size is suitable for being attached in anastomotic stoma, and anastomotic stoma is covered comprehensively, makes the epidermal growth factor (EGF) of its release can repair anastomotic stoma comprehensively.
Further, described polylactic acid membrane width 30mm, length 90mm; Described polylactic acid frame length, width are 5mm.The esophagus size that meets human body covers anastomotic stoma comprehensively, not only saves material but also can produce a desired effect.
Further again, the described polylactic acid membrane stacking has five.Between five polylactic acid membranes, clip four layers of epidermal growth factor sublayer, epidermal growth factor (EGF) is slowly discharged, the consumption release along with polylactic acid membrane, reaches the effect that continued treatment is put medicine.
Accompanying drawing explanation
Below in conjunction with drawings and Examples, technical solutions of the utility model are further illustrated:
Fig. 1 is the schematic diagram that this utility model is applied to the polylactic acid paster embodiment of Operation on Esophageal Cancer;
Fig. 2 is the sectional schematic diagram of A-A in Fig. 1.
The specific embodiment
As shown in Figures 1 and 2, this utility model is applied to the polylactic acid paster of Operation on Esophageal Cancer, comprises the polylactic acid membrane 2 stacking and is wrapped in the polylactic acid frame 1 outside polylactic acid membrane 2, in the polylactic acid membrane 2 stacking, between every layer of polylactic acid membrane 2, is provided with epidermal growth factor sublayer 3; Described polylactic acid membrane 2 width 30mm, length 90mm; Described polylactic acid frame 1 length, width are 5mm, and thickness is 1mm; The described polylactic acid membrane stacking 2 has five.
In specific implementation process, between five polylactic acid membranes 2, be provided with four layers of gelatinous epidermal growth factor sublayer 3, during operation, in operation process, the polylactic acid paster that this utility model is applied to Operation on Esophageal Cancer is attached in the anastomotic stoma of esophagus, make it all cover anastomotic stoma, first, the part of ground floor polylactic acid membrane 2 and polylactic acid frame 1 is absorbed by tissue, discharge ground floor epidermal growth factor sublayer 3, then, As time goes on, organize and absorb gradually the second layer, the 3rd layer, the 4th layer of polylactic acid membrane 2 and part polylactic acid frame 1, discharge gradually the second layer simultaneously, the 3rd layer, the 4th layer of gelatinous epidermal growth factor sublayer 3, finally tissue absorbs layer 5 polylactic acid membrane 2, through 7-10 days, discharge, the cell increment effect of 3 pairs of epidermal growth factor sublayers, promote anastomotic healing.
Certainly, if polylactic acid membrane 2 width are 20mm, 22mm, 24mm, 25mm, 26mm, 28mm, 32mm, 34mm, 35mm, 38mm, 40mm, 42mm, 44mm, 45mm, 48mm or 50mm, length 80mm, 82mm, 84mm, 85mm, 88mm, 92mm, 94mm, 95mm, 98 mm or 100mm; Described polylactic acid frame 1 length, width are 3 mm, 4 mm, 6mm, 7mm or 8mm, all within protection domain.
For a person skilled in the art; do not departing under the prerequisite of this utility model structure; can also make some distortion and improvement, these also should be considered as protection domain of the present utility model, and these can not affect effect and practical applicability that this utility model is implemented.
Claims (4)
1. the polylactic acid paster that is applied to Operation on Esophageal Cancer, is characterized in that: comprise the polylactic acid membrane stacking and be wrapped in the polylactic acid frame outside polylactic acid membrane, being provided with epidermal growth factor sublayer in the polylactic acid membrane stacking between every layer of polylactic acid membrane.
2. the polylactic acid paster that is applied to Operation on Esophageal Cancer as claimed in claim 1, is characterized in that: described polylactic acid membrane width 20-50mm, length 80-100mm; Described polylactic acid frame length, width are 3-8mm, and thickness is 1mm.
3. the polylactic acid paster that is applied to Operation on Esophageal Cancer as claimed in claim 2, is characterized in that: described polylactic acid membrane width 30mm, length 90mm; Described polylactic acid frame length, width are 5mm.
4. the polylactic acid paster that is applied to Operation on Esophageal Cancer as claimed in claim 3, is characterized in that: the described polylactic acid membrane stacking has five.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320406721.3U CN203400400U (en) | 2013-07-10 | 2013-07-10 | Polylactic acid paster used for esophagus cancer operation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201320406721.3U CN203400400U (en) | 2013-07-10 | 2013-07-10 | Polylactic acid paster used for esophagus cancer operation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN203400400U true CN203400400U (en) | 2014-01-22 |
Family
ID=49936344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201320406721.3U Expired - Fee Related CN203400400U (en) | 2013-07-10 | 2013-07-10 | Polylactic acid paster used for esophagus cancer operation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN203400400U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117298083A (en) * | 2023-05-08 | 2023-12-29 | 北京肿瘤医院(北京大学肿瘤医院) | Application of D-lactic acid in preparation of medicines for treating and/or preventing esophageal squamous cell carcinoma |
-
2013
- 2013-07-10 CN CN201320406721.3U patent/CN203400400U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117298083A (en) * | 2023-05-08 | 2023-12-29 | 北京肿瘤医院(北京大学肿瘤医院) | Application of D-lactic acid in preparation of medicines for treating and/or preventing esophageal squamous cell carcinoma |
| CN117298083B (en) * | 2023-05-08 | 2024-02-20 | 北京肿瘤医院(北京大学肿瘤医院) | Application of D-lactic acid in preparation of medicines for treating and/or preventing esophageal squamous cell carcinoma |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Down-regulating scar formation by microneedles directly via a mechanical communication pathway | |
| Kobayashi et al. | Prevention of esophageal strictures after endoscopic submucosal dissection | |
| CN102921050A (en) | Preparation method of anti-adhesion fibrous membrane with hemostatic function | |
| IN2012DN03120A (en) | ||
| Varkarakis et al. | Treatment of axillary hidradenitis with transposition flaps: a 6-year experience | |
| CN203400400U (en) | Polylactic acid paster used for esophagus cancer operation | |
| CN110257515B (en) | Molecular marker for breast cancer diagnosis and application thereof | |
| Tang et al. | Multifunctional hydrogels for wound dressings using xanthan gum and polyacrylamide | |
| AR082411A1 (en) | SYRNA AIMED AT VEGFA AND IN VIVO TREATMENT METHODS | |
| Timmermans et al. | Early oral intake after total laryngectomy does not increase pharyngocutaneous fistulization | |
| RU2018118552A (en) | APPLICATION OF NEUREGULIN FOR TREATING DAMAGE TO PERIPHERAL NERVES | |
| Shi et al. | Progress on the prevention of esophageal stricture after endoscopic submucosal dissection | |
| Malmsjö et al. | Green foam, black foam or gauze for NWPT: effects on granulation tissue formation | |
| CN102908649A (en) | Anti-adhesion fibrous membrane with hematostatic function | |
| CN104874012A (en) | Fluffy type skin collagen hemostatic material and preparation method thereof | |
| Wu et al. | Modulation of lymphangiogenesis in incisional murine diabetic wound healing using negative pressure wound therapy | |
| US20210361833A1 (en) | Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation | |
| Asukai et al. | A case report of a 19‐week gravid patient with a dehisced abdominal wound and treated with VAC ATS® Therapy System | |
| CN113546217A (en) | Modified acellular myocardial matrix gel and preparation method thereof | |
| Zhang et al. | Supramolecular elastomer based on polydimethylsiloxanes (SESi) film: synthesis, characterization, biocompatibility, and its application in the context of wound dressing | |
| Abboud et al. | Cervical neck dissection without drainage in papillary thyroid carcinoma | |
| CN101974170B (en) | Chitosan hemostatic sponge made from maggot shells as well as preparation method and application thereof | |
| CN102533982A (en) | New use of human gene KLF8 in tumor treatment | |
| CN114209877B (en) | Preparation method of antibacterial gel with polyethyleneimine as gel matrix | |
| Okolugbo | Treatment outcomes of auricular hematoma using corrugated rubber drains: a pilot study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140122 Termination date: 20150710 |
|
| EXPY | Termination of patent right or utility model |